+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
FEMALE
ID04802759

Study of Multiple Treatment Combinations for Breast Cancer Evaluating Safety and Effectiveness in an Open-Label Randomized Design

Led by Hoffmann-La Roche · Updated on 2026-11-03

316

Participants Needed

32

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating multiple treatment combinations for women with breast cancer that is inoperable, locally advanced, or metastatic. This Phase IbII open-label study includes participants with estrogen receptor-positive ER, HER2-positive or negative breast cancer, some with specific mutations or prior treatment histories. The study allows flexibility to open, close, or modify treatment groups based on ongoing results and patient needs. Participants receive various drugs orally or by subcutaneous injection, including giredestrant alone or combined with other drugs like abemaciclib, ipatasertib, inavolisib, ribociclib, everolimus, samuraciclib, atezolizumab, and a fixed-dose combination of pertuzumab and trastuzumab. Dosage schedules vary, commonly using 28-day or 21-day cycles, continuing until unacceptable side effects or disease progression. Different cohorts focus on distinct breast cancer subtypes and prior treatments, and the study monitors responses over time. During the study, participants undergo evaluations including tumor measurements using RECIST v1.1 criteria, imaging for heart function, and biomarker testing from tumor or blood samples. Researchers assess tumor response, disease control, survival, and adverse events throughout treatment and follow-up up to six years. Safety is closely monitored, and participants may have tumor biopsies if treatment changes occur. The study aims to understand how effective and safe these treatment combinations are for different breast cancer patient groups.

CONDITIONS

Brief Title

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Research Team

R

Reference Study ID Number: CO42867 https://forpatients.roche.com/ No attachments to email below.

F

Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here